PDCD1 and neoplasm: Moreover, some researchers found that the frequency of PD1+ CD8+ T cells in the tumor microenvironment, which negatively impacts effector and immunosuppressive functions, can predict the clinical efficacy of PD1 inhibitors better than PD1 or PD‐L1 expression or TMB.30